**Core tip:** Serotonin reuptake inhibitors (SRIs) are a very commonly prescribed medication. The use of SRIs is reportedly associated with an increased risk for gastrointestinal bleeding in few studies. In this retrospective cohort study we analyzed the association between use of SRI and risk of post sphincterotomy bleeding with meticulous exclusion of all the confounders associated with increased risk of sphincterotomy bleeding. To our knowledge, this is a first study to assess the SRIs impact on post sphincterotomy bleeding.

INTRODUCTION
============

Since its earliest description in 1974, endoscopic sphincterotomy has become a commonly performed procedure for a variety of therapeutic indications during endoscopic retrograde cholangiopancreatography (ERCP)\[[@B1]\]. Including choledocholithiasis, placement of stents through malignant and benign strictures, as well as to treat dysfunction of the sphincter of Oddi. It is a technically difficult endoscopic procedure performed under visual and fluoroscopic guidance. It involves deep insertion of the cannula into the bile duct through the ampulla of Vater and the subsequent use of electrocautery to incise the sphincter of Oddi. Sphincterotomy has been associated with pancreatitis, hemorrhage, perforation and other complications most of which occur within the initial 24 h of procedure\[[@B2],[@B3]\]. Hemorrhage is a well-known complication occurring in up to 2%-7% of all cases\[[@B1]\].

Serotonin reuptake inhibitors (SRIs) are considered to be a first-line pharmacologic therapy for depression, and are among the most commonly prescribed medications in the United States. The safety and side effect profile of these drugs have been well-described in the existing literature. In numerous studies, SRI therapy has been associated with an increased risk of gastrointestinal bleeding. Similarly, the use of non-steroidal anti-inflammatory drugs (NSAIDs), anticoagulants and aspirin has been associated with an increased risk of bleeding during sphincterotomy procedures\[[@B4]\]. These drugs are typically discontinued a week prior to the procedure date. Our aim was to evaluate the risk of immediate and delayed bleeding following sphincterotomy procedure. Our hypothesis was that SRIs medications increase the risk of post sphincterotomy bleeding.

MATERIALS AND METHODS
=====================

Definitions
-----------

Immediate post endoscopic sphincterotomy (post-ES) bleeding is considered to be oozing of blood during ERCP. Delayed post ES bleeding occurs within 10 d after ERCP and manifested as melena, hematemesis or hematochezia (Table [1](#T1){ref-type="table"}). Classification of bleeding according to Cotton et al\[[@B3]\] states mild bleeding is defined as hemoglobin drop of less than 3 g/dL without the need of transfusion, moderate bleeding is considered when blood transfusion of 4 units or less is required without any surgical intervention, severe bleeding is defined as blood transfusion of 5 units or more and surgical intervention is required (Table [2](#T2){ref-type="table"}).

###### 

Complications of sphincterotomy and risk factors for hemorrhage

  **Complications of sphincterotomy**                                                                                         **Risk factors for hemorrhage**
  --------------------------------------------------------------------------------------------------------------------------- ---------------------------------
  Pancreatitis - 1.0%-15.7% (Most common complication)                                                                        Presence of coagulopathy
  Hemorrhage - 2%-7%                                                                                                          Use of anti-coagulation
  Cholangitis - 1% - (Fever, chills, elevated liver enzymes, and/or positive blood culture within 48 h after the procedure)   Cholangitis
  Cholecystitis - (Clinical and radiographic evidence of an inflamed gallbladder)                                             Low endoscopist case volume

###### 

Bleeding grading system

  **Mild**                                                                                                  **Moderate**                                 **Severe**
  --------------------------------------------------------------------------------------------------------- -------------------------------------------- --------------------------------------------
  Transfusion is not required, with evidence of bleeding                                                    Transfusion of 4 units or less is required   Transfusion of 5 units or more is required
  Hemoglobin drop of less than 3 g/dL                                                                       No surgical intervention                     Angiographic or surgical intervention
  Immediate bleeding - seen in 30% patients (8) - endoscopic venous oozing which stopped with epinephrine                                                
  Delayed bleeding - occur up to 2 wk after the procedure - hematemesis, melena, haematochezia                                                           
  Severe bleeding - 0.1%-0.5%                                                                                                                            

Adapt from Cotton et al\[[@B3]\].

Patient selection
-----------------

This retrospective cohort study was conducted after obtaining necessary approval from the Institution Review Board and patients consent. Patients who underwent ERCP with sphincterotomy at a tertiary referral center by a group of ten therapeutic endoscopists with a minimum of 5 years of experience during the study period of January 2006 - September 2015 were reviewed. One of the confounding factor of bleeding is low endoscopist case volume (Table [1](#T1){ref-type="table"}). This study was conducted at a tertiary referral center with an average 2500 ERCP are performed in a year, in total 22500 during 2006-2015. SRI is a commonly prescribed drug in United States. Patients using either selective SRIs or serotonin-norepinephrine reuptake inhibitors (SNRIs) at the time of the procedure were included (Table [3](#T3){ref-type="table"}). The patients were grouped according to whether they continued to take SRIs until the day of the procedure and patients who never had been on SRI's or SNRI's. Patients SRI dose wasn't included as the purpose of study was to analysis bleeding risk with SRI therapy. Patients with following risk factors that could independently increase the risk of bleeding (such as coagulopathies, liver disorders, and cholangitis), patients taking aspirin and NSAIDs, patients with abnormal lab values for PT-INR \> 1.5, platelet count \< 150000, and PTT \> 25 s were excluded from the study (Figure [1](#F1){ref-type="fig"}). Data pertaining to the patient demographics (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}), technical aspects of the procedure (Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}), medical co-morbidities including renal, cardiac, hepatic issues, coagulation disorder, bleeding disorder, history of alcohol intake, drug history, coagulation profile, platelet levels, recent antiplatelet or NSAID use was abstracted.

![Exclusion criteria.](WJGE-9-171-g001){#F1}

###### 

Serotonin reuptake inhibitors medications included in the study

  **Serotonin reuptake inhibitors**   **Serotonin-norepinephrine reuptake inhibitors**
  ----------------------------------- --------------------------------------------------
  Citalopram (Celexa)                 Desvenlafaxine (Pristiq)
  Escitalopram (Lexapro, Cipralex)    Duloxetine (Cymbalta)
  Paroxetine (Paxil, Seroxat)         Levomilnacipran (Fetzima)
  Fluoxetine (Prozac)                 Milnacipran (Ixel, savella)
  Fluvoxamine (Luvox)                 Tofenacin (Elamol, tofacine)
  Sertraline (Zoloft, lustral)        Venlafaxine (Effexor)

###### 

Patient demographics *n* (%)

  **Factor**                **Overall (*n* = 447)**   **SRI (*n* = 219)**   **No SRI (*n* = 228)**   ***P* value**                       
  ------------------------- ------------------------- --------------------- ------------------------ --------------- ----- ------------- ------------------------------------------
  Age (yr)                  445                       64.4 ± 17.9           219                      64.0 ± 16.8     226   64.7 ± 19.0   0.68[1](#T4FN1){ref-type="table-fn"}
  Male                      447                       112 (25.1)            219                      47 (21.5)       228   65 (28.5)     0.086[3](#T4FN2){ref-type="table-fn"}
  BMI                       442                       29.5 ± 7.5            218                      29.7 ± 7.6      224   29.3 ± 7.4    0.59[1](#T4FN1){ref-type="table-fn"}
  Smoking                   435                       216 (49.7)            216                      114 (52.8)      219   102 (46.6)    0.20[3](#T4FN2){ref-type="table-fn"}
  Alcohol use               432                       161 (37.3)            215                      69 (32.1)       217   92 (42.4)     0.027[3](#T4FN2){ref-type="table-fn"}
  Cardiovascular disorder   447                       111 (24.8)            219                      53 (24.2)       228   58 (25.4)     0.76[3](#T4FN2){ref-type="table-fn"}
  Depression                445                       160 (36.0)            219                      99 (45.2)       226   61 (27.0)     \< 0.001[3](#T4FN2){ref-type="table-fn"}
  Renal disease             447                       55 (12.3)             219                      30 (13.7)       228   25 (11.0)     0.38[3](#T4FN2){ref-type="table-fn"}
  Intestinal disease        447                       66 (14.8)             219                      29 (13.2)       228   37 (16.2)     0.37[3](#T4FN2){ref-type="table-fn"}
  History of UGI bleed      389                       1 (0.26)              207                      0 (0.0)         182   1 (0.55)      0.47[4](#T4FN3){ref-type="table-fn"}

ANOVA; ^2^Kruskal-Wallis test;

Pearson\'s *χ*^2^ test;

Fisher\'s exact test. Intestinal diseases: Peptic ulcer, inflammatory bowel disease. Values presented as Mean ± SD or *n* (%). SRI: Serotonin reuptake inhibitor.

###### 

Patients lab values

  **Factor**    **Overall (*n* = 447)**   **SRI (*n* = 219)**   **No SRI (n = 228)**   ***P* value**                       
  ------------- ------------------------- --------------------- ---------------------- --------------- ----- ------------- --------------------------------------
  PPI           447                       111 (24.8)            219                    51 (23.3)       228   60 (26.3)     0.46[2](#T5FN2){ref-type="table-fn"}
  Platelets     435                                             213                                    222                 0.59[1](#T5FN1){ref-type="table-fn"}
  140-400                                 432 (99.3)                                   212 (99.5)            220 (99.1)    
  \> 400                                  3 (0.69)                                     1 (0.47)              2 (0.90)      
  INR           391                                             190                                    201                 \-
  0.9-1.2                                 391 (100.0)                                  190 (100.0)           201 (100.0)   
  PTT           361                                             171                                    190                 \-
  24.7-32.7 s                             361 (100.0)                                  171 (100.0)           190 (100.0)   

Kruskal-Wallis test;

Pearson\'s *χ*^2^ test. Values presented as Mean ± SD or *n* (%). SRI: Serotonin reuptake inhibitor.

###### 

Number of endoscopic retrograde cholangiopancreatography

  **Number of ERCPs**   **Overall (*n* = 447)**   **SRI (*n* = 219 )**   **No SRI (*n* = 228)**   ***P* value**
  --------------------- ------------------------- ---------------------- ------------------------ --------------------------------------
  1                     432 (96.6)                214 (97.7)             218 (95.6)               0.23[1](#T6FN1){ref-type="table-fn"}
  2                     13 (2.9)                  3 (1.4)                10 (4.4)                 
  3                     2 (0.45)                  2 (0.91)               0 (0.0)                  

Kruskal-Wallis test. Values presented as *n* (%).SRI: Serotonin reuptake inhibitor; ERCP: Endoscopic retrograde cholangiopancreatography.

###### 

Indications for endoscopic retrograde cholangiopancreatography

                                           **Overall (*n* = 447)**   **SRI (*n* = 219)**   **No SRI (*n* = 228)**   ***P* value**   
  ---------------------------------------- ------------------------- --------------------- ------------------------ --------------- ---------------------------------------
  Abnormal CT                              16 (3.8)                                        9 (4.3)                  7 (3.3)         0.57[1](#T7FN1){ref-type="table-fn"}
  Abdominal pain                           90 (21.2)                                       43 (20.6)                47 ( 21.9)      0.75[1](#T7FN1){ref-type="table-fn"}
  Abnormal LFT                             62 (14.6)                                       32 (15.3)                30 (14.0)       0.69[1](#T7FN1){ref-type="table-fn"}
  Biliary dilation                         8 (1.9)                                         6 (2.9)                  2 (0.93)        0.17[2](#T7FN2){ref-type="table-fn"}
  Bile duct stones                         187 (44.1)                                      96 (45.9)                91 (42.3)       0.45[1](#T7FN1){ref-type="table-fn"}
  Complications of prior biliary surgery   6 (1.4)                                         4 (1.9)                  2 (0.93)        0.44[2](#T7FN2){ref-type="table-fn"}
  Jaundice                                 49 (11.6)                                       16 (7.7)                 33 (15.3)       0.013[1](#T7FN1){ref-type="table-fn"}
  Cholangitis                              9 (2.1)                   209                   4 (1.9)                  5 (2.3)         0.99[2](#T7FN2){ref-type="table-fn"}

Pearson\'s *χ*^2^ test;

Fisher\'s exact test. Values presented as *n* (%). CT: Computed tomography; LFT: Lung function testing; SRI: Serotonin reuptake inhibitor.

Statistical analysis
--------------------

Continuous variables are presented as mean ± SD or median (25^th^, 75^th^ percentiles) and categorical factors as frequency (percentage). A univariable analysis was performed to assess differences between subjects who used SRIs at the time of ERCP and those who did not. Analysis of variance or the non-parametric Kruskal-Wallis tests were used for continuous or ordinal variables and Pearson's *χ*^2^ tests were used for categorical factors. In addition, univariable and multivariable logistic regression analyses were performed to assess factors associated with occurrence of post-sphincterotomy bleeding; factors seen in \< 5 patients were not considered for this part of the analysis. An automated stepwise variable selection method performed on 1000 samples was used to choose the final model. The use of SRI was forced into the models and the additional three variables with highest inclusion rates were included in the final models. A *P* value \< 0.05 was considered statistically significant. SAS version 9.4 (The SAS Institute, Cary, NC) was used to perform all analyses.

RESULTS
=======

Out of 22500 who had undergone endoscopy, 447 subjects who underwent sphincterotomy were included in the study (Tables [5](#T5){ref-type="table"}-[7](#T7){ref-type="table"}). At the time of the procedure, 219 patients were taking SRI therapy and 228 patients had never been on SRI therapy.

There was no evidence of a significant difference in the incidence of post-sphincterotomy bleeding between the groups 8.2% *vs* 12.3% (Table [8](#T8){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). The absence of alcohol intake, depression, and lower PTT were significantly more common in subjects taking SRIs.

![Post-sphincterotomy bleeding.](WJGE-9-171-g002){#F2}

###### 

Bleeding and management

                                 **Overall (*n* = 447)**   **SRI (*n* = 219)**   **No SRI (*n* = 228)**   ***P* value**               
  ------------------------------ ------------------------- --------------------- ------------------------ --------------- ----------- ---------------------------------------
  Post-sphincterotomy bleeding   46 (10.3)                 219                   18 (8.2)                 228             28 (12.3)   0.16[1](#T8FN1){ref-type="table-fn"}
  Injected with epinephrine      25 (54.3)                 18                    7 (38.9)                 28              18 (64.3)   0.091[1](#T8FN1){ref-type="table-fn"}

Pearson\'s *χ*^2^ test;. Values presented *n* (%). SRI: Serotonin reuptake inhibitor.

On univariable analysis, there was no evidence of an association between any of the assessed factors and post-sphincterotomy bleeding. The use of SRIs, demographic, BMI, clinical comorbidities including cardiovascular disorders, renal disease, indication of ERCP, and number of ERCPs were included in the final model but these did not reach statistical significance. None of the patients who experienced immediate post-sphincterotomy bleeding required blood transfusion therapy. Only two patients \< 1% of the study group experienced delayed bleeding and did not require any transfusion. Patients who oozed blood were managed by injecting epinephrine.

DISCUSSION
==========

It is a widely perceived, yet never before tested in patients undergoing sphincterotomy, theory that the use of SRI therapy is associated with an increased risk of gastrointestinal bleeding. In this retrospective cohort study, we found no significant association between the use of SRI and post-sphincterotomy bleeding. Moreover, no difference in estimated blood loss was observed in these two group. Association between percutaneous endoscopic gastrostomy and SRI's bleeding has been reported\[[@B5]\]; however, unlike our study, none of these studies excluded other confounding potential risk factors for bleeding. Our findings contradict the other studies that have found SRI to increase bleeding. The exact mechanism is unknown but the purported mechanism of SRI's on bleeding states that SRI's inhibits the serotonin transport protein and by blocking the uptake of synaptic serotonin into presynaptic neurons, it impairs the hemostasis function. SRI's act as a blocker and inhibit entry of serotonin from blood into platelets. Release of serotonin from platelets into the bloodstream during an injury is an important step platelet aggregation\[[@B9],[@B11]-[@B13]\]. This presumed mechanism can further predispose to bleeding disturbances. However, our finding did not show any evidence indicating SRI to increase bleeding.

Many studies suggest an association between SRI's and upper gastrointestinal bleeding. It's suggested that SRIs increase gastric acidity by targeting gastric mucosa which potentiates the risk of upper GI bleeding\[[@B9],[@B11]\]. In a recent meta-analysis on risk for GI bleeds, it was noticed that patients on combined therapy such as NSAIDs, aspirin, SRIs were at higher risk for bleeding\[[@B8]\]. To our knowledge, only two studies have studied risk of post sphincterotomy bleeding with patients using NSAIDS and aspirin. The finding of the studies were equivocal: Both found different results suggesting the safety of aspirin use during procedure\[[@B4],[@B6]\] one study results showed that use of aspirin resulted in increased risk of bleeding\[[@B6]\], and the other study results showed aspirin and NSAIDs not associated with the risk bleeding\[[@B4]\].

Drugs that cause prolonged bleeding, such as aspirin and NSAIDS are advised to discontinue a week prior to surgery. Patients who experience bleeding during the procedure are injected with epinephrine around the sphincterotomy site. This is considered to be the most commonly used method to manage immediate bleeding.

Our usual approach is local therapy in the form of 1:10000 diluted epinephrine injection, either alone or in combination with cautery, hemoclips. Covered metal stents are placed in patients who are expected to resume therapeutic anticoagulation or have underlying coagulopathy.

While recognizing that no definite guidelines can be derived from this retrospective study, our result presented here provides novel knowledge about complex question of management of SRI's prior to therapeutic ERCP. We conclude if the confounding variables for bleeding are excluded, SRI's alone do not increase the risk of post-sphincterotomy bleeding. According to our knowledge, this is the first study to assess the SRI's impact on post sphincterotomy bleeding.

COMMENTS
========

Background
----------

Since its earliest description in 1974, endoscopic sphincterotomy has become a commonly performed procedure for a variety of therapeutic indications during endoscopic retrograde cholangio-pancreatography. Including choledocholithiasis, placement of stents through malignant and benign strictures, as well as to treat dysfunction of the sphincter of Oddi.

Research frontiers
------------------

The authors hypothesis was that serotonin reuptake inhibitors (SRIs) medications increase the risk of post sphincterotomy bleeding.

Innovations and breakthroughs
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The authors conclude if the confounding variables for bleeding are excluded, SRI's alone do not increase the risk of post-sphincterotomy bleeding. According to our knowledge, this is the first study to assess the SRI's impact on post sphincterotomy bleeding.

Peer-review
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The paper of Yadav et al is original and well written. The interest to know there is no bleeding risk with SRI therapy is not so high but important to know.
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